Get the app Watchlists Portfolios Alerts Sign in Get started

Menu

Market-Moving News for December 1st

Benzinga Newsdesk Dec 1, 2025 11 months ago

MoversTrading Ideas

QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic

QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties

DYAI: 35% | Dyadic Applied BioSolutions And BRIG BIO Signs Development And Commercialization Agreement To Jointly Develop And Commercialize Recombinant Bovine Alpha-Lactalbumin

NIO: -8% | NIO Delivers 36,275 Vehicles In November Up 76.3% Year Over Year With Cumulative Deliveries Reaching 949,457

Read the original